Today, a brief rundown of news involving Merck and Vanda Pharmaceuticals, as well as updates from Sanofi and Novo Holdings that you may have missed. If approved, Regeneron’s proposal to buy 23andMe ...

At least that is what Vanda Research reckons. The firm’s Retail Capitulation index — which it says captures not just net purchases but also purchases’ breadth, sentiment, leverage ...

The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a stomach condition characterized by delayed gastric emptying. Vanda ...

Vanda Pharmaceuticals (NASDAQ:VNDA) is alleging that members of the U.S. FDA "have committed to delay" its request for a hearing to discuss the agency's issuing of a Complete Response Letter in ...